Hedge fund SAC Capital and experts from Gradient Statistics and Banc of the USA face charges of stock cost manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA created negative reviews on Biovail's earnings quality. Simultaneously, SAC built a sizable short position within the stock. The accused must consider specific and general proper reactions to those accusations.
Estimated Submission On |